Chronotherapy is the timing of medications to circadian rhythms to optimize beneficial and minimize adverse outcomes. We reviewed the US Online Prescribers' Digital Reference for the specified administration schedule of medications prescribed to manage coronary heart disease (CHD) and its major risk factors. For arterial hypertension, dosing of terazosin and guanfacine is recommended in the evening and thiazide, thiazide-like, and sulfonamide diuretics morning; Verapamil (Verelan®) morning, its "PM" formulation evening, and long-acting diltiazem (Cardizem® LA), per clinical goal, morning or evening. Most hyperlipidemia medications are recommended in the evening. Many hyperglycemia medications are intended for morning ingestion, but, when indicated, some may be prescribed in unequal doses or intervals. For obesity, administration of appetite suppressant psychostimulants and sympathomimetics is stipulated for morning ingestion. Sleep insufficiency medications are to be taken before bedtime. For tobacco dependence, transdermal nicotine patch application is recommended in the morning, and bupropion early, but not late, during the wake span. For alcohol dependence, disulfiram is intended for morning ingestion. For thromboembolism prophylaxis, factor Xa inhibitor rivaroxaban is recommended at dinner and low-dose acetylsalicylic acid before bedtime. Medications for angina pectoris and edema of congestive heart failure are stipulated for morning administration. Overall, >200 medications prescribed to manage CHD and its risk factors qualify as chronotherapies.
Gold nanoparticles (NPs) were prepared by reduction with salicylic acid in aqueous solution. The resulting dispersions were found to contain a mixture of flat triangular/hexagonal and smaller close-to-spherical NPs. As expected from theoretical considerations, such nanocolloids display two clearly differentiated surface plasmon bands at 540 and 860 nm associated with spherical and anisotropic triangular/hexagonal NPs, respectively. Layer-by-layer (LBL) assembly was used to deposit thin films of the Au colloids. UV−visible data indicate preferential adsorption of the flat particles on polyelectrolyte films. Importantly, a new band developed at 650 nm as the number of the Au NPs bilayers increased. This finding indicates that there exists a strong interaction between the NPs in adjacent layers, resulting in the surface plasmon absorption at a new wavelength. The insertion of extra polyelectrolyte or montmorillonite layers between the Au bilayers was shown to gradually reduce the interlayer interaction and resulted in the NP composite films with absorption spectra virtually identical to those of the original dispersion. The bilayer deposition sequence in LBL assembly, i.e. multilayer architecture, can be used to control the strength of NP−NP coupling in the layered composites.
